Chicago, Ill., Sept. 15, 2017 — Bioprinting startup BIOLIFE4D has named accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC as Chief Medical Officer, further bolstering its world-class leadership team. BIOLIFE4D is a pioneering biotech company focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant.
Joining the BIOLIFE4D team, Morgan adds to his leadership responsibilities as Surgical Director of Mechanical Circulatory Support and Cardiac Transplantation at Texas Heart Institute. The renowned facility performed the first successful cardiac transplantation in the U.S. in 1968 and the first clinical implant of a total artificial heart in 1969.
“BIOLIFE4D is committed to assembling a truly world class team with the expertise to help us deliver on our mission to build hearts and save lives,” said BIOLIFE4D CEO Steven Morris. “We believe that the ability to bioprint a human heart suitable for transplant is within BIOLIFE4D’s grasp, and we are honored that Dr. Morgan is working with us to make that a reality.”
Morgan, a seasoned academic and medical professional, also holds multiple positions of leadership at Baylor College of Medicine, including Chief of the Division of Cardiothoracic Transplantation and Circulatory Support; Surgical Director for the Advanced Heart Failure Center of Excellence, and the Lester and the Sue Smith Endowed Chair of Surgery.
With the goal of making organ replacement commercially viable and commonplace globally BIOLIFE4D’s approach will combine recent breakthroughs in regenerative medicine, stem cell biology, 3D printing techniques and computing technology.
“Heart disease is such a devastating illness, and for those with advanced heart failure, the unfortunate reality is that current transplant options typically end up being available to only a fraction of those in need,” said Dr. Morgan. “BIOLIFE4D is getting the right science and medical people in the room to fundamentally change the heart transplant paradigm, and I’m proud to be part of such a brilliant team of motivated professionals.”
In his role as Chief Medical Officer, Morgan will collaborate on bioprinting and transplant process development with the BIOLIFE4D Scientific Advisory Team led by Adam Feinberg, Ph.D. Feinberg is Associate Professor of Materials Science & Engineering and Biomedical Engineering at Carnegie Mellon University and Principal Investigator of the Regenerative Biomaterials and Therapeutics Group.
Other members of the BIOLIFE4D team include:
Ibrahim Ozbolat, Ph.D. – Associate Professor of Engineering Science and Mechanics in the Biomedical Engineering Department and Huck Institutes of the Life Sciences at Penn State University, and Principal Investigator at the Ozbolat Lab.
Sean Palecek, Ph.D. – Professor of Chemical and Biological Engineering at the University of Wisconsin at Madison and Principal Investigator at the Palecek Group.
Shayn Peirce-Cottler, Ph.D. – Professor of Biomedical Engineering at the University of Virginia and Principal Investigator at the Peirce-Cottler Laboratory.
Ramille Shah, Ph.D. – Assistant Professor of Materials Science & Engineering in the McCormick School of Engineering at Northwestern University and Principal Investigator at the Shah Tissue Engineering and Additive Manufacturing Lab.
Raimond Winslow, Ph.D. – Director of the Institute for Computational Medicine, Director of the Center for Cardiovascular Bioinformatics and Modeling, and Professor of Biomedical Engineering at Johns Hopkins University.
Janet Zoldan, Ph.D. – Assistant Professor of Biomedical Engineering at the University of Texas at Austin and Principal Investigator at The Zoldan Group.
BIOLIFE4D recently filed a $50 million initial public offering with the Securities and Exchange Commission (SEC) under Regulation A+ equity crowdfunding rules, allowing everyday investors to help the company bring its groundbreaking cardiac tissue regeneration and organ replacement process to market. The “Reg A+” rules, outlined under the 2012 Jumpstart Our Business Startups (JOBS) Act, allow companies to raise up to $50 million in equity from non-accredited investors and others.
To learn more about BIOLIFE4D and to express interest in investing visit https://biolife4d.com/invest/.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time. With BIOLIFE4D, a patient-specific, fully functioning heart will be created through 3D bioprinting using the patient’s own cells – eliminating the well-known challenges of organ rejection and long donor waiting lists that plague existing organ transplant methods. Financed through equity crowdfunding, BIOLIFE4D is driving a movement to transform the treatment of heart disease, the leading cause of death among both men and women globally. Learn more and invest at www.biolife4d.com.
Although you are currently able to express your interest in investing, BIOLIFE4D Corporation is not yet accepting investments. No money or other consideration is being solicited by the company at this time, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement is qualified, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of its acceptance given after the qualification date. If you indicate interest, your indication of interest involves no obligation or commitment of any kind.